A Phase 2 interventional study of Semaglutide and Firsocostat in Nonalcoholic Steatohepatitis, sponsored by Gilead Sciences. Completed at 18 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-15.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 13th largest by enrollment, is the only one that started in 2019, is one of 11 in phase 2, and was the 15th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 161 across the 16 interventional studies. Of the 16 that completed or were terminated, 15 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).
Key Inclusion Criteria:
Screening laboratory parameters, as determined by central laboratory:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) for 24 weeks
Drug: Semaglutide
Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg for 24 weeks
Drug: Semaglutide · Drug: Firsocostat
Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 30 mg for 24 weeks
Drug: Semaglutide · Drug: Cilofexor
Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 100 mg for 24 weeks
Drug: Semaglutide · Drug: Cilofexor
Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks
Drug: Semaglutide · Drug: Firsocostat · Drug: Cilofexor
Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
Tablets administered orally once daily
Also known as: GS-0976
Tablets administered orally once daily
Also known as: GS-9674
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Treatment-emergent adverse events (TEAEs) were defined as, any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug. Participants were assessed for AEs according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: First dose date up to Week 24 plus 30 days
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities, defined as values that increase at least one toxicity grade from baseline at any time post-baseline up to and including the date of last dose of study drug plus 30 days, were summarized by treatment group. Graded laboratory abnormalities were defined using the grading scheme in the CTCAE 5.0.
Time frame: First dose date up to 24 weeks plus 30 days
Participants were enrolled at study sites in United States. The first participant was screened on 29 July 2019. The last study visit occurred on 13 July 2020.
| Milestone | Semaglutide | Semaglutide + Firsocostat 20 mg | Semaglutide + Cilofexor 30 mg | Semaglutide + Cilofexor 100 mg | Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg |
|---|---|---|---|---|---|
| Started | 21 | 22 | 22 | 22 | 21 |
| Completed | 18 | 20 | 21 | 18 | 19 |
| Not completed | 3 | 2 | 1 | 4 | 2 |
| Withdrew: Withdrew consent | 1 | 1 | 0 | 2 | 1 |
| Withdrew: Adverse event | 2 | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Investigator's discretion | 0 | 0 | 0 | 1 | 0 |
Treatment-emergent adverse events (TEAEs) were defined as, any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug. Participants were assessed for AEs according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
| percentage of participants | Semaglutide | Semaglutide + Firsocostat 20 mg | Semaglutide + Cilofexor 30 mg | Semaglutide + Cilofexor 100 mg | Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 81.0 | 86.4 | 81.8 | 72.7 | 90.5 |
Treatment-emergent laboratory abnormalities, defined as values that increase at least one toxicity grade from baseline at any time post-baseline up to and including the date of last dose of study drug plus 30 days, were summarized by treatment group. Graded laboratory abnormalities were defined using the grading scheme in the CTCAE 5.0.
| percentage of participants | Semaglutide | Semaglutide + Firsocostat 20 mg | Semaglutide + Cilofexor 30 mg | Semaglutide + Cilofexor 100 mg | Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg |
|---|---|---|---|---|---|
| Grade 1 | 61.9 | 63.6 | 36.4 | 50.0 | 66.7 |
| Grade 2 | 23.8 | 22.7 | 31.8 | 18.2 | 9.5 |
| Grade 3 | 0.0 | 4.5 | 0.0 | 0.0 | 0.0 |
| Grade 4 | 0.0 | 0.0 | 0.0 | 9.1 | 0.0 |
Collected over First dose date up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Semaglutide | 0/21 (0%) | 1/21 (4.8%) | 16/21 (76.2%) |
| Semaglutide + Firsocostat 20 mg | 0/22 (0%) | 0/22 (0%) | 17/22 (77.3%) |
| Semaglutide + Cilofexor 30 mg | 0/22 (0%) | 0/22 (0%) | 18/22 (81.8%) |
| Semaglutide + Cilofexor 100 mg | 0/22 (0%) | 1/22 (4.5%) | 13/22 (59.1%) |
| Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg | 0/21 (0%) | 0/21 (0%) | 17/21 (81%) |
| Event | Semaglutide | Semaglutide + Firsocostat 20 mg | Semaglutide + Cilofexor 30 mg | Semaglutide + Cilofexor 100 mg | Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/21 | 0/22 | 0/22 | 0/22 | 0/21 |
| VomitingGastrointestinal disorders | 1/21 | 0/22 | 0/22 | 0/22 | 0/21 |
| PancreatitisGastrointestinal disorders | 0/21 | 0/22 | 0/22 | 1/22 | 0/21 |
| Event | Semaglutide | Semaglutide + Firsocostat 20 mg | Semaglutide + Cilofexor 30 mg | Semaglutide + Cilofexor 100 mg | Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 9/21 | 3/22 | 8/22 | 6/22 | 14/21 |
| VomitingGastrointestinal disorders | 1/21 | 2/22 | 2/22 | 1/22 | 6/21 |
| Decreased appetiteMetabolism and nutrition disorders | 4/21 | 4/22 | 6/22 | 0/22 | 3/21 |
| ConstipationGastrointestinal disorders | 2/21 | 2/22 | 5/22 | 3/22 | 5/21 |
| DiarrhoeaGastrointestinal disorders | 5/21 | 4/22 | 5/22 | 1/22 | 3/21 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/21 | 0/22 | 0/22 | 2/22 | 0/21 |
| Abdominal painGastrointestinal disorders | 1/21 | 4/22 | 1/22 | 1/22 | 2/21 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/21 | 4/22 | 1/22 | 0/22 | 0/21 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/21 | 2/22 | 4/22 | 0/22 | 0/21 |
| Abdominal pain upperGastrointestinal disorders | 3/21 | 1/22 | 1/22 | 0/22 | 2/21 |
The Safety Analysis Set included participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Semaglutide | Semaglutide + Firsocostat 20 mg | Semaglutide + Cilofexor 30 mg | Semaglutide + Cilofexor 100 mg | Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 55 ± 10.4 | 52 ± 12.6 | 51 ± 10.9 | 54 ± 10.8 | 53 ± 11.4 | 53 ± 11.1 |
| Sex: Female, Male(Participants) | Semaglutide | Semaglutide + Firsocostat 20 mg | Semaglutide + Cilofexor 30 mg | Semaglutide + Cilofexor 100 mg | Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg | Total |
|---|---|---|---|---|---|---|
| Female | 15 | 15 | 16 | 13 | 15 | 74 |
| Male | 6 | 7 | 6 | 9 | 6 | 34 |
| Race/Ethnicity, Customized(Participants) | Semaglutide | Semaglutide + Firsocostat 20 mg | Semaglutide + Cilofexor 30 mg | Semaglutide + Cilofexor 100 mg | Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 1 | 1 | 4 |
| Asian | 2 | 2 | 2 | 1 | 0 | 7 |
| Black | 1 | 0 | 1 | 1 | 0 | 3 |
| White | 17 | 19 | 18 | 19 | 19 | 92 |
| Other | 0 | 1 | 0 | 0 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Semaglutide | Semaglutide + Firsocostat 20 mg | Semaglutide + Cilofexor 30 mg | Semaglutide + Cilofexor 100 mg | Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg | Total |
|---|---|---|---|---|---|---|
| Not Hispanic or Latino | 13 | 10 | 17 | 15 | 10 | 65 |
| Hispanic or Latino | 8 | 12 | 5 | 7 | 11 | 43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Jul 2020, 11 months.
Results were first posted in Jul 2021, 1 year after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 11 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Firsocostat · Cilofexor
Non-alcoholic Fatty Liver Disease →